More tools

BioAtla, Inc.

BCAB

BioAtla, Inc.

0.35

0.01

(1.85%)

Today

As of 4:00 PM Eastern

After Hours:

0.35

-0.00

(-0.34%)

Options AI - All Directions

Apr 17 Expected Move

See where the options market thinks BCAB will move from here.

News

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Arthur He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Fourth Quarter and Fiscal Year 2024 Earnings Call.

seekingalpha.com • Mar 27, 2025 18:18 Eastern
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript
BioAtla Cuts 30% of Jobs in Restructuring Effort

The San Diego biopharmaceutical company, which focuses on treating solid tumor cancers, said Thursday its workforce reduction is part of an effort to extend its runway beyond key clinical readouts in the first half of 2026.

marketwatch.com • Mar 27, 2025 17:05 Eastern
BioAtla Cuts 30% of Jobs in Restructuring Effort
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided highlights on its clinical programs.

globenewswire.com • Mar 27, 2025 16:05 Eastern
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26–29, 2025 and in Scottsdale, AZ from March 27–29, 2025, respectively.

globenewswire.com • Mar 20, 2025 08:00 Eastern
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights.

globenewswire.com • Mar 19, 2025 08:00 Eastern
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AXL Inhibitors - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 16+ companies and 20+ pipeline drugs in AXL Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence AXL Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve AXL Inhibitors. AXL Inhibitors Emerging Drugs Chapters This segment of the AXL Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Emerging Drugs

globenewswire.com • Mar 04, 2025 07:34 Eastern
AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com • Jan 02, 2025 13:10 Eastern
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know